Shilpan Shah VIEW CLINICAL PROFILE

Shilpan Shah, MBBS

Assistant Professor of Clinical Medicine, Academic Institute
Houston Methodist
Weill Cornell Medical College


VIEW CLINICAL PROFILE
Active Clinical Trials

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

NCT04965493

Publications

Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia
Shao, J, Shah, S, Ganguly, S, Zu, Y, He, C & Li, Z 2023, , Clinical Epigenetics, vol. 15, no. 1, 134. https://doi.org/10.1186/s13148-023-01547-0

Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine
Shao, J, Shah, S, Ganguly, S, Zu, Y, He, C & Li, Z 2023, , Genes, vol. 14, no. 6, 1180. https://doi.org/10.3390/genes14061180

Long-term outcomes in patients with Burkitt lymphoma older than 65 years: an analysis of the Texas Cancer Registry
Burns, EA, Wilson, JJ, Mathur, S, Kieser, R, Gong, Z, Hu, CCA, Tang, CHA, Petkova, J, Yuen, C, Mai, H, Shah, S, Rice, L, Ganguly, S & Pingali, SR 2023, , Annals of Hematology, vol. 102, no. 10, pp. 2753-2763. https://doi.org/10.1007/s00277-023-05328-w

Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry
Burns, EA, Sanchez, CG, Mathur, S, Guerrero, C, Muhsen, IN, Sarfraz, H, Hu, CCA, Tang, CHA, Shah, SS, Tremont, IW, Teh, B, Ganguly, S & Pingali, SRK 2023, , Annals of Hematology, vol. 102, no. 5, pp. 1111-1120. https://doi.org/10.1007/s00277-023-05140-6

Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia
Shao, J, Wang, S, West-Szymanski, D, Karpus, J, Shah, S, Ganguly, S, Smith, J, Zu, Y, He, C & Li, Z 2022, , Scientific Reports, vol. 12, no. 1, 12410, pp. 12410. https://doi.org/10.1038/s41598-022-16685-3

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma
Gentille, C, Sarfraz, H, Joshi, J, Randhawa, J, Shah, S & Pingali, SR 2022, , Cancer Reports, vol. 5, no. 7, e1581, pp. e1581. https://doi.org/10.1002/cnr2.1581

Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement
Mooneyham, J, Gentille, C, Barbieri, A & Shah, S 2020, , BMJ Case Reports, vol. 13, no. 9, 235412. https://doi.org/10.1136/bcr-2020-235412

The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: A report of three cases
Burns, EA, Anand, K, Chung, B, Shah, S, Randhawa, JK & Pingali, SR 2020, , ecancermedicalscience, vol. 14, 1011. https://doi.org/10.3332/ECANCER.2020.1011

Multiple myeloma with concurrent immune thrombocytopenic purpura
Sarfraz, H, Anand, K, Liu, S & Shah, S 2020, , ecancermedicalscience, vol. 14, 1012. https://doi.org/10.3332/ECANCER.2020.1012

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia
Shah, S, Loghavi, S, Garcia-Manero, G & Khoury, JD 2014, , Journal of Hematology and Oncology, vol. 7, no. 1, 26. https://doi.org/10.1186/1756-8722-7-26

Targeted therapy for HER2 positive breast cancer
Incorvati, JA, Shah, S, Mu, Y & Lu, J 2013, , Journal of Hematology and Oncology, vol. 6, no. 1, 38. https://doi.org/10.1186/1756-8722-6-38

VIEW FULL PUBLICATIONS